Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
4.32
+0.07 (1.53%)
Market open: Aug 12, 2026, 2:27 PM EDT
4.21
-0.04 (-0.94%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | CEO & Director |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Mr. David D. House | Senior VP of Finance & Principal Financial Officer |
| Mr. Peter Hubbard | Vice President of Operations |
| Ms. Bani Tchekanova Ph.D. | Head of Regulatory Strategy & Operations |
| Date | Type | Document |
|---|---|---|
| 2026-07-20 | 8-K | tm2620782d2_8k.htm |
| 2026-07-13 | S-8 | tm2619826d1_s8.htm |
| 2026-06-24 | 8-K/A | tm2618503d2_8ka.htm |
| 2026-06-23 | 8-K | tm2618503d1_8k.htm |
| 2026-06-16 | 8-K | tm2618097d1_8k.htm |
| 2026-05-13 | 10-Q | armp-20260331x10q.htm |
| 2026-05-07 | 8-K | tm2613773d1_8k.htm |
| 2026-04-27 | DEF 14A | armp-20260611xdef14a.htm |
| 2026-04-27 | 8-K | tm2610924d1_8k.htm |
| 2026-04-02 | 8-K | tm2610924d1_8k.htm |